Deutsche Bank raised the firm’s price target on Genmab (GMAB) to DKK 1,900 from DKK 1,750 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab receives FDA Breakthrough Therapy Designation for rinatabart sesutecan
- Genmab’s Strategic Growth and Clinical Advancements: A Compelling Investment Opportunity
- Genmab’s Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Genmab price target raised to $36 from $35 at H.C. Wainwright
- Genmab’s Tisotumab Vedotin Study: A Promising Update for Solid Tumor Treatment